Merck topped first-quarter sales estimates as Winrevair and injectable Keytruda Qlex helped support revenue growth.

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

By Deena Beasley and Mariam Sunny April 30 (Reuters) - Merck on Thursday beat first-quarter sales expectations on strong ...

The drugmaker posted $16.29 billion in quarterly revenue, topping Wall Street forecasts, though a big acquisition charge ...

Q1 earnings beat lifts shares; 2026 guidance narrows as Keytruda grows, Gardasil declines and R&D jumps on deals.

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda ...

Merck faces falling sales for other key drugs including a blockbuster HPV vaccine and diabetes medication.

Merck is scheduled to report first-quarter earnings on April 30, during market hours, with analysts expecting a strong ...

As Merck considers its life after Keytruda, much will depend on the performance of a pair of respiratory products it gained ...

Merck & Co reported a loss in Q1 due to acquisition charges despite increased cancer and respiratory drugs sales. Revenue was $16.3 billion, beating estimates. Keytruda sales rose 12% to $8 billion, ...

Merck's Q1 sales surpassed expectations, driven by strong demand for Keytruda. Despite acquisition-related losses, investors ...

Merck & Co beat market forecasts with its first-quarter results on Thursday and raised its full-year guidance on the back of ...